Immunotherapy with depigmented glutaraldehyde-polymerized extracts: changes in quality of life
Summary Background Immunotherapy (IT) with modified allergens reduces allergic rhinitis (AR) symptoms and medications requirements. Improvement of quality of life (QOL) is a key point in the treatment of AR. The aim of this study was to provide evidence of changes related to the patient's QOL (...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental allergy 2005-05, Vol.35 (5), p.572-578 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 578 |
|---|---|
| container_issue | 5 |
| container_start_page | 572 |
| container_title | Clinical and experimental allergy |
| container_volume | 35 |
| creator | Alvarez-Cuesta, E. Aragoneses-Gilsanz, E. Martín-Garcia, C. Berges-Gimeno, P. Gonzalez-Mancebo, E. Cuesta-Herranz, J. |
| description | Summary
Background
Immunotherapy (IT) with modified allergens reduces allergic rhinitis (AR) symptoms and medications requirements. Improvement of quality of life (QOL) is a key point in the treatment of AR. The aim of this study was to provide evidence of changes related to the patient's QOL (well‐being) induced by a modified (depigmented glutaraldehyde‐polymerized) therapeutic vaccine and of its safety.
Material and Methods
Fifty‐three patients with a well‐documented clinical history of seasonal AR sensitized to Dactylis glomerata and Olea europaea pollens were included in a randomized clinical trial. Twenty‐five patients (Group‐A) received a mixture of D. glomerata and O. europaea pollen extracts and 28 patients received placebo (group‐C). Any adverse event was recorded and graded in accordance with EAACI guidelines. RQLQ was recorded before the treatment (pollen season 2000) and after 1 year of treatment (pollen season 2001). Dose–response skin prick test with each allergen extract was conducted at baseline and at the end of the study.
Results
Each patient received 17 injections during this period. All patients completed the trial and no systemic adverse reactions were recorded. Symptom scores (P |
| doi_str_mv | 10.1111/j.1365-2222.2005.02245.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17492370</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17492370</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4935-ac39eda44870a008b4717d6ab33f185018075884d5f0be5cf14becaa700e08d43</originalsourceid><addsrcrecordid>eNqNkV2L1DAUhoso7rj6F6QIeteaNEmTCF4sw37BogiKe2VI09OZjOnHJi079deb7gy74JXn5hw4z3s4vG-SpBjlONbHXY5JybIiVl4gxHJUFJTl-2fJ6nHxPFkhyWjGhaQnyasQdgghwqR4mZxgJqSQnK-SX9dtO3X9uAWvhzm9t-M2rWGwmxa6Eep046ZRe-1q2M41ZEPv5ha8_RNXsB-9NmP4lJqt7jYQUtuld5N2dpzTvkmdbeB18qLRLsCbYz9Nflycf19fZTdfL6_XZzeZoZKwTBsiodaUCo40QqKiHPO61BUhDRYMYYE4E4LWrEEVMNNgWoHRmiMESNSUnCYfDncH399NEEbV2mDAOd1BPwWFOZUF4SiC7_4Bd_3ku_ibwlLKQpZYREgcIOP7EDw0avC21X5WGKklALVTi89q8VktAaiHANQ-St8e709VC_WT8Oh4BN4fAR2Mdo3XnbHhiSt5SQpeRO7zgbu3Dub_fkCtz8-WKeqzg96GEfaPeu1_q5ITztTPL5eK3rKSXNwW6hv5C66wsLc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>199929618</pqid></control><display><type>article</type><title>Immunotherapy with depigmented glutaraldehyde-polymerized extracts: changes in quality of life</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Alvarez-Cuesta, E. ; Aragoneses-Gilsanz, E. ; Martín-Garcia, C. ; Berges-Gimeno, P. ; Gonzalez-Mancebo, E. ; Cuesta-Herranz, J.</creator><creatorcontrib>Alvarez-Cuesta, E. ; Aragoneses-Gilsanz, E. ; Martín-Garcia, C. ; Berges-Gimeno, P. ; Gonzalez-Mancebo, E. ; Cuesta-Herranz, J.</creatorcontrib><description>Summary
Background
Immunotherapy (IT) with modified allergens reduces allergic rhinitis (AR) symptoms and medications requirements. Improvement of quality of life (QOL) is a key point in the treatment of AR. The aim of this study was to provide evidence of changes related to the patient's QOL (well‐being) induced by a modified (depigmented glutaraldehyde‐polymerized) therapeutic vaccine and of its safety.
Material and Methods
Fifty‐three patients with a well‐documented clinical history of seasonal AR sensitized to Dactylis glomerata and Olea europaea pollens were included in a randomized clinical trial. Twenty‐five patients (Group‐A) received a mixture of D. glomerata and O. europaea pollen extracts and 28 patients received placebo (group‐C). Any adverse event was recorded and graded in accordance with EAACI guidelines. RQLQ was recorded before the treatment (pollen season 2000) and after 1 year of treatment (pollen season 2001). Dose–response skin prick test with each allergen extract was conducted at baseline and at the end of the study.
Results
Each patient received 17 injections during this period. All patients completed the trial and no systemic adverse reactions were recorded. Symptom scores (P<0.001) and medication requirements (P<0.001) were significantly reduced in the IT group during the pollen season. This patient group also experienced greater and statistically significant improvement in overall RQLQ score and in five of the seven domains, all of them surpassing the threshold of ‘minimal important difference’ of 0.5 points.
Conclusions
Results of this study provided evidence that IT with depigmented, glutaraldehyde‐modified allergen extracts was well‐tolerated and added beneficial effects to AR treatment in pollen allergic patients eliciting an improvement in QOL enough to justify a change in the patient's treatment.</description><identifier>ISSN: 0954-7894</identifier><identifier>EISSN: 1365-2222</identifier><identifier>DOI: 10.1111/j.1365-2222.2005.02245.x</identifier><identifier>PMID: 15898977</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Adolescent ; Adult ; Allergic diseases ; Asthma - complications ; Asthma - immunology ; Biological and medical sciences ; Cross-Linking Reagents - adverse effects ; Cross-Linking Reagents - therapeutic use ; Dactylis glomerata ; Dose-Response Relationship, Immunologic ; Double-Blind Method ; Female ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Glutaral - adverse effects ; Glutaral - therapeutic use ; Humans ; Immunopathology ; Immunotherapy, Active - methods ; Male ; Medical sciences ; Middle Aged ; Olea europaea ; Patient Compliance ; Plant Extracts - adverse effects ; Plant Extracts - therapeutic use ; pollen ; Pollen - adverse effects ; Pollen - immunology ; polymerized vaccines ; Quality of Life ; Rhinitis, Allergic, Seasonal - complications ; Rhinitis, Allergic, Seasonal - drug therapy ; Rhinitis, Allergic, Seasonal - immunology ; RQLQ ; safety ; Skin Tests ; specific immunotherapy ; therapeutic vaccine ; Treatment Outcome ; Vaccines, Conjugate - therapeutic use</subject><ispartof>Clinical and experimental allergy, 2005-05, Vol.35 (5), p.572-578</ispartof><rights>2005 INIST-CNRS</rights><rights>Copyright Blackwell Publishing May 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4935-ac39eda44870a008b4717d6ab33f185018075884d5f0be5cf14becaa700e08d43</citedby><cites>FETCH-LOGICAL-c4935-ac39eda44870a008b4717d6ab33f185018075884d5f0be5cf14becaa700e08d43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2222.2005.02245.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2222.2005.02245.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16763272$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15898977$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alvarez-Cuesta, E.</creatorcontrib><creatorcontrib>Aragoneses-Gilsanz, E.</creatorcontrib><creatorcontrib>Martín-Garcia, C.</creatorcontrib><creatorcontrib>Berges-Gimeno, P.</creatorcontrib><creatorcontrib>Gonzalez-Mancebo, E.</creatorcontrib><creatorcontrib>Cuesta-Herranz, J.</creatorcontrib><title>Immunotherapy with depigmented glutaraldehyde-polymerized extracts: changes in quality of life</title><title>Clinical and experimental allergy</title><addtitle>Clin Exp Allergy</addtitle><description>Summary
Background
Immunotherapy (IT) with modified allergens reduces allergic rhinitis (AR) symptoms and medications requirements. Improvement of quality of life (QOL) is a key point in the treatment of AR. The aim of this study was to provide evidence of changes related to the patient's QOL (well‐being) induced by a modified (depigmented glutaraldehyde‐polymerized) therapeutic vaccine and of its safety.
Material and Methods
Fifty‐three patients with a well‐documented clinical history of seasonal AR sensitized to Dactylis glomerata and Olea europaea pollens were included in a randomized clinical trial. Twenty‐five patients (Group‐A) received a mixture of D. glomerata and O. europaea pollen extracts and 28 patients received placebo (group‐C). Any adverse event was recorded and graded in accordance with EAACI guidelines. RQLQ was recorded before the treatment (pollen season 2000) and after 1 year of treatment (pollen season 2001). Dose–response skin prick test with each allergen extract was conducted at baseline and at the end of the study.
Results
Each patient received 17 injections during this period. All patients completed the trial and no systemic adverse reactions were recorded. Symptom scores (P<0.001) and medication requirements (P<0.001) were significantly reduced in the IT group during the pollen season. This patient group also experienced greater and statistically significant improvement in overall RQLQ score and in five of the seven domains, all of them surpassing the threshold of ‘minimal important difference’ of 0.5 points.
Conclusions
Results of this study provided evidence that IT with depigmented, glutaraldehyde‐modified allergen extracts was well‐tolerated and added beneficial effects to AR treatment in pollen allergic patients eliciting an improvement in QOL enough to justify a change in the patient's treatment.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Allergic diseases</subject><subject>Asthma - complications</subject><subject>Asthma - immunology</subject><subject>Biological and medical sciences</subject><subject>Cross-Linking Reagents - adverse effects</subject><subject>Cross-Linking Reagents - therapeutic use</subject><subject>Dactylis glomerata</subject><subject>Dose-Response Relationship, Immunologic</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Glutaral - adverse effects</subject><subject>Glutaral - therapeutic use</subject><subject>Humans</subject><subject>Immunopathology</subject><subject>Immunotherapy, Active - methods</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Olea europaea</subject><subject>Patient Compliance</subject><subject>Plant Extracts - adverse effects</subject><subject>Plant Extracts - therapeutic use</subject><subject>pollen</subject><subject>Pollen - adverse effects</subject><subject>Pollen - immunology</subject><subject>polymerized vaccines</subject><subject>Quality of Life</subject><subject>Rhinitis, Allergic, Seasonal - complications</subject><subject>Rhinitis, Allergic, Seasonal - drug therapy</subject><subject>Rhinitis, Allergic, Seasonal - immunology</subject><subject>RQLQ</subject><subject>safety</subject><subject>Skin Tests</subject><subject>specific immunotherapy</subject><subject>therapeutic vaccine</subject><subject>Treatment Outcome</subject><subject>Vaccines, Conjugate - therapeutic use</subject><issn>0954-7894</issn><issn>1365-2222</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkV2L1DAUhoso7rj6F6QIeteaNEmTCF4sw37BogiKe2VI09OZjOnHJi079deb7gy74JXn5hw4z3s4vG-SpBjlONbHXY5JybIiVl4gxHJUFJTl-2fJ6nHxPFkhyWjGhaQnyasQdgghwqR4mZxgJqSQnK-SX9dtO3X9uAWvhzm9t-M2rWGwmxa6Eep046ZRe-1q2M41ZEPv5ha8_RNXsB-9NmP4lJqt7jYQUtuld5N2dpzTvkmdbeB18qLRLsCbYz9Nflycf19fZTdfL6_XZzeZoZKwTBsiodaUCo40QqKiHPO61BUhDRYMYYE4E4LWrEEVMNNgWoHRmiMESNSUnCYfDncH399NEEbV2mDAOd1BPwWFOZUF4SiC7_4Bd_3ku_ibwlLKQpZYREgcIOP7EDw0avC21X5WGKklALVTi89q8VktAaiHANQ-St8e709VC_WT8Oh4BN4fAR2Mdo3XnbHhiSt5SQpeRO7zgbu3Dub_fkCtz8-WKeqzg96GEfaPeu1_q5ITztTPL5eK3rKSXNwW6hv5C66wsLc</recordid><startdate>200505</startdate><enddate>200505</enddate><creator>Alvarez-Cuesta, E.</creator><creator>Aragoneses-Gilsanz, E.</creator><creator>Martín-Garcia, C.</creator><creator>Berges-Gimeno, P.</creator><creator>Gonzalez-Mancebo, E.</creator><creator>Cuesta-Herranz, J.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope></search><sort><creationdate>200505</creationdate><title>Immunotherapy with depigmented glutaraldehyde-polymerized extracts: changes in quality of life</title><author>Alvarez-Cuesta, E. ; Aragoneses-Gilsanz, E. ; Martín-Garcia, C. ; Berges-Gimeno, P. ; Gonzalez-Mancebo, E. ; Cuesta-Herranz, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4935-ac39eda44870a008b4717d6ab33f185018075884d5f0be5cf14becaa700e08d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Allergic diseases</topic><topic>Asthma - complications</topic><topic>Asthma - immunology</topic><topic>Biological and medical sciences</topic><topic>Cross-Linking Reagents - adverse effects</topic><topic>Cross-Linking Reagents - therapeutic use</topic><topic>Dactylis glomerata</topic><topic>Dose-Response Relationship, Immunologic</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Glutaral - adverse effects</topic><topic>Glutaral - therapeutic use</topic><topic>Humans</topic><topic>Immunopathology</topic><topic>Immunotherapy, Active - methods</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Olea europaea</topic><topic>Patient Compliance</topic><topic>Plant Extracts - adverse effects</topic><topic>Plant Extracts - therapeutic use</topic><topic>pollen</topic><topic>Pollen - adverse effects</topic><topic>Pollen - immunology</topic><topic>polymerized vaccines</topic><topic>Quality of Life</topic><topic>Rhinitis, Allergic, Seasonal - complications</topic><topic>Rhinitis, Allergic, Seasonal - drug therapy</topic><topic>Rhinitis, Allergic, Seasonal - immunology</topic><topic>RQLQ</topic><topic>safety</topic><topic>Skin Tests</topic><topic>specific immunotherapy</topic><topic>therapeutic vaccine</topic><topic>Treatment Outcome</topic><topic>Vaccines, Conjugate - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alvarez-Cuesta, E.</creatorcontrib><creatorcontrib>Aragoneses-Gilsanz, E.</creatorcontrib><creatorcontrib>Martín-Garcia, C.</creatorcontrib><creatorcontrib>Berges-Gimeno, P.</creatorcontrib><creatorcontrib>Gonzalez-Mancebo, E.</creatorcontrib><creatorcontrib>Cuesta-Herranz, J.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Clinical and experimental allergy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alvarez-Cuesta, E.</au><au>Aragoneses-Gilsanz, E.</au><au>Martín-Garcia, C.</au><au>Berges-Gimeno, P.</au><au>Gonzalez-Mancebo, E.</au><au>Cuesta-Herranz, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunotherapy with depigmented glutaraldehyde-polymerized extracts: changes in quality of life</atitle><jtitle>Clinical and experimental allergy</jtitle><addtitle>Clin Exp Allergy</addtitle><date>2005-05</date><risdate>2005</risdate><volume>35</volume><issue>5</issue><spage>572</spage><epage>578</epage><pages>572-578</pages><issn>0954-7894</issn><eissn>1365-2222</eissn><abstract>Summary
Background
Immunotherapy (IT) with modified allergens reduces allergic rhinitis (AR) symptoms and medications requirements. Improvement of quality of life (QOL) is a key point in the treatment of AR. The aim of this study was to provide evidence of changes related to the patient's QOL (well‐being) induced by a modified (depigmented glutaraldehyde‐polymerized) therapeutic vaccine and of its safety.
Material and Methods
Fifty‐three patients with a well‐documented clinical history of seasonal AR sensitized to Dactylis glomerata and Olea europaea pollens were included in a randomized clinical trial. Twenty‐five patients (Group‐A) received a mixture of D. glomerata and O. europaea pollen extracts and 28 patients received placebo (group‐C). Any adverse event was recorded and graded in accordance with EAACI guidelines. RQLQ was recorded before the treatment (pollen season 2000) and after 1 year of treatment (pollen season 2001). Dose–response skin prick test with each allergen extract was conducted at baseline and at the end of the study.
Results
Each patient received 17 injections during this period. All patients completed the trial and no systemic adverse reactions were recorded. Symptom scores (P<0.001) and medication requirements (P<0.001) were significantly reduced in the IT group during the pollen season. This patient group also experienced greater and statistically significant improvement in overall RQLQ score and in five of the seven domains, all of them surpassing the threshold of ‘minimal important difference’ of 0.5 points.
Conclusions
Results of this study provided evidence that IT with depigmented, glutaraldehyde‐modified allergen extracts was well‐tolerated and added beneficial effects to AR treatment in pollen allergic patients eliciting an improvement in QOL enough to justify a change in the patient's treatment.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>15898977</pmid><doi>10.1111/j.1365-2222.2005.02245.x</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0954-7894 |
| ispartof | Clinical and experimental allergy, 2005-05, Vol.35 (5), p.572-578 |
| issn | 0954-7894 1365-2222 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_17492370 |
| source | MEDLINE; Wiley Journals |
| subjects | Adolescent Adult Allergic diseases Asthma - complications Asthma - immunology Biological and medical sciences Cross-Linking Reagents - adverse effects Cross-Linking Reagents - therapeutic use Dactylis glomerata Dose-Response Relationship, Immunologic Double-Blind Method Female Fundamental and applied biological sciences. Psychology Fundamental immunology Glutaral - adverse effects Glutaral - therapeutic use Humans Immunopathology Immunotherapy, Active - methods Male Medical sciences Middle Aged Olea europaea Patient Compliance Plant Extracts - adverse effects Plant Extracts - therapeutic use pollen Pollen - adverse effects Pollen - immunology polymerized vaccines Quality of Life Rhinitis, Allergic, Seasonal - complications Rhinitis, Allergic, Seasonal - drug therapy Rhinitis, Allergic, Seasonal - immunology RQLQ safety Skin Tests specific immunotherapy therapeutic vaccine Treatment Outcome Vaccines, Conjugate - therapeutic use |
| title | Immunotherapy with depigmented glutaraldehyde-polymerized extracts: changes in quality of life |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T20%3A37%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunotherapy%20with%20depigmented%20glutaraldehyde-polymerized%20extracts:%20changes%20in%20quality%20of%20life&rft.jtitle=Clinical%20and%20experimental%20allergy&rft.au=Alvarez-Cuesta,%20E.&rft.date=2005-05&rft.volume=35&rft.issue=5&rft.spage=572&rft.epage=578&rft.pages=572-578&rft.issn=0954-7894&rft.eissn=1365-2222&rft_id=info:doi/10.1111/j.1365-2222.2005.02245.x&rft_dat=%3Cproquest_cross%3E17492370%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=199929618&rft_id=info:pmid/15898977&rfr_iscdi=true |